+ Watch DSCO
on My Watchlist
A biotechnology company, which develops its proprietary surfactant technology as Surfactant Replacement Therapies for respiratory disorders and diseases.
Valuation already anticipates slow launch for Surfaxin (infant respiratory distress syndrome or RDS), but is missing the game changer development of Aerosurf (aerosolized inhalation, also for infant RDS, but avoids the intubation required for Surfaxin and all competition). Recent financing extends cash runwat through Surfaxin launch and aerosurf 2b studies in mid 15. Attractive target.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions